Jorge Castillo MD

Hematologic Oncology

Physician at Dana-Farber Cancer Institute

450 Brookline AveBoston, MA 02215
Phone+1 617-632-6285

Dr. Castillo is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Castillo's full profile Already have an account?

Summary

Dr. Jorge Castillo is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Dana-Farber Cancer Institute and Brigham and Women's Hospital. He received his medical degree from Autonomous Metropolitan University Xochimilco and has been in practice 21 years. He specializes in hematologic oncology and is experienced in Waldenstrom macroglobulinemia, lymphoma and myeloma.

Education & Training

Rhode Island Hospital/Brown University HealthFellowship, Hematology and Medical Oncology, 2005 - 2008
MetroWest Medical CenterResidency, Internal Medicine, 2002 - 2005
Autonomous Metropolitan University XochimilcoClass of 1996

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2022 - Present
MA State Medical License 2013 - 2028
NH State Medical License 2023 - 2028
RI State Medical License 2005 - 2008
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2017
CMS Meaningful Use Stage 1 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2017

Clinical Trials

Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
COMPLETED
PHASE2
Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia
TERMINATED
PHASE2
Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
COMPLETED
PHASE2

Publications & Presentations

PubMed

Plasmablastic Lymphoma: 2026 Update on Diagnosis, Risk Stratification, and Management.
Jorge J Castillo, Brady E Beltrán, Jorge A Florindez, Julio C Chavez, Luis Malpica
American Journal of Hematology. 2026-08-01
Real-world outcomes of plasmablastic lymphoma: Treatment approaches and survival outcomes in the PLASMABLAT-001 cohort.
Humberto Martinez-Cordero, Paola Spirko, Irma Karen Pellon, Laura Korin, Perla R Colunga-Pedraza
Leukemia Research. 2026-08-01
WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's Macroglobulinemia.
Maria Luisa Guerrera, Xia Liu, Nickolas Tsakmaklis, Abigail L Peachey, Amanda Kofides
Blood Cancer Journal. 2026-07-08

Journal Articles

TP53 Mutations Are Associated with Mutated MYD88 and CXCR4, and Confer an Adverse Outcome in Waldenström Macroglobulinaemia
Toni Dubeau, Steven P Treon, Jorge J Castillo, Christopher J Patterson, British Journal of Haematology
Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom Macroglobulinemia
Ghobrial IM, Redd R, Armand P, Boswell E, Chuma S, Huynh D, Sacco A, Roccaro A, Noonan K, Leblebjian H, Warren D, Henrick P, Castillo JJ, Richardson PG, Matous J, Well..., Leukemia, 1/3/2015
Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (Alliance) clinical trials
Castillo JJ, Mulkey F, Geyer S, Kolitz JE, Blum W, Powell BL, George SL,Larson RA, Stone RM, American Journal of Hematology, 1/3/2015

Books/Book Chapters

Non-Hodgkin Lymphoma: Models, Prognostic Factors and Targets
Chapter: Prognostic factors in HIV-associated lymphoma
Page 153 - 169Layton JL, Castillo JJEditors: Quesenberry PJ, Castillo JJ.Springer Science + Business Media, New York, NY2013
Non-Hodgkin Lymphoma: Models, Prognostic Factors and Targets
Chapter: Prognostic factors in T-cell lymphoma
Page 141 - 152Beltran BE, Castillo JJEditors: Quesenberry PJ, Castillo JJ.Springer Science + Business Media, New York, NY2013
Abeloff's Clinical Oncology
Chapter: Special Issues in Pregnancy
Page 914 - 925Castillo JJ, Rizack TEditors: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper J.Elsevier, Philadelphia, PAEdition 5th,2012

Abstracts/Posters

Assessment of Different Biological Variables (Serum Albumin, _-2-Microglobulin, Lymphocyte/Monocyte ratio, Neutrophil/Lymphocyte ratio, Platelet/Lymphocyte ratio) in a...
Jorge J. Castillo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Novel HCK and BTK Dual Inhibitor Kin-8194 Shows Superior Activity over Ibrutinib and Overcomes BTKC481S Mediated Ibrutinib Resistance in Vitro and In Vivo in MYD88 M...
Jorge J. Castillo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Multi-Institutional Validation of the Prognostic and Predictive Value of the Neutrophil-to-Lymphocyte Ratio in Patients with Diffuse Large B- Cell Lymphoma: A Study ...
Jorge J. Castillo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

CXCR4 Mutational Status Does Not Impact Outcomes in Patients with Waldenstrom Macroglobulinemia Treated with Proteasome Inhibitors
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenstr_m Macroglobulinemia Treated with Ibrutinib
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Comprehensive Geriatric Assessment in Elderly Patients with Aggressive Non-Hodgkin Lymphoma in Peru
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Other

Waldenstrom Macroglobulinemia
Castillo JJ, Ghobrial IM, Decision Support in Medicine (TM), Clinical Decision Support: Hematology
https://www.decisionsupportinmedicine.com
1/1/2014
Autoimmune Hemolytic Anemia (including Evans Syndrome)
Castillo JJ, Decision Support in Medicine (TM), Clinical Decision Support: Hematology
https://www.decisionsupportinmedicine.com
1/1/2013

Press Mentions

Researchers Devise a Progression Risk-Based Classification for Patients with Asymptomatic Waldenström MacroglobulinemiaApril 23rd, 2019
Study Shows Who Survives Burkitt LymphomaFebruary 10th, 2016